Magnetic Field Rotating / MyD88 Cancer Research Results

MFrot, Magnetic Field Rotating: Click to Expand ⟱
Features:
Rotary Magnetic field can be generated by a spinning magnet or magnets. Or it can be implemented with 2 or more coils, power with a phase shift between them (90 deg for 2 coil implementation) (60deg for 3 coil implementation)
Targets affected are mostly the same as for Magnet fields
Main differences
- may enhance the EPR effect allowing targeting of drugs to cancer cells
- acts as wireless stirrer, especially on magnetic particles(inducing eddy currents in water media)
- research for use in nano surgery, and mechanical destruction of cancer cells
- continue to highlight ability to raise ROS in cancer cell and lower ROS in normal cells
- RMF may be responsible for Ca2+ distribution to pass across the plasma membrane(differental affected for cancer and normal cells)

Pathways:
- induce ROS production in cancer cells, while decreasing ROS in normal cells. Ca2+ is critical and the Ca2+ balance is increased in cancer cells while decreased in normal cells (example for wound healing)
- ROS↑ related: MMP↓(ΔΨm), Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, RhoA↓, NF-κB↓, TGF-β↓, ERK↓
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓,
- Others: PI3K↓, AKT↓, Wnt↓, AMPK, ERK↓, JNK,
- Synergies: < Others(review target notes), Neuroprotective, Cognitive,

- Selectivity: Cancer Cells vs Normal Cells

Rotating Magnetic Fields
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS (tumor-selective oxidative stress) ↑ ROS (P→R); sustained to cytotoxicity (G) ↔ minimal change or transient ↑ without injury (P→R) P, R, G Primary stress amplifier Oncomagnetic reports emphasize selective tumor ROS increase with normal-cell sparing in comparable exposure conditions
2 Mitochondrial ETC inhibition (Complex I/NADH:ubiquinone) ↓ Complex I / respiration (P→R) ↔ limited effect (P→R) P, R Bioenergetic collapse trigger Rotating/spinning fields are proposed to disrupt mitochondrial electron flow, driving ROS elevation upstream of ΔΨm loss
3 Ca²⁺ signaling (ER–mitochondria Ca²⁺ transfer / mitochondrial Ca²⁺ load) ↑ Ca²⁺ dysregulation (P→R) contributing to mitochondrial failure (G) ↔ buffered Ca²⁺ homeostasis (P→R) P, R, G Amplifies ETC/ROS-driven toxicity RMF-driven mitochondrial stress can propagate via Ca²⁺ transfer to accelerate ΔΨm loss and pro-death ER stress in tumor cells while sparing normal cells
4 Mitochondrial permeability transition pore (MPTP) ↑ sustained MPTP opening (R→G) ↔ resistant to opening P, R, G Mitochondrial point-of-no-return RMF-enhanced ROS and Ca²⁺ loading promote persistent MPTP opening in tumor mitochondria, driving energetic collapse and apoptosis while normal cells remain below the opening threshold
5 ΔΨm / mitochondrial membrane integrity ↓ ΔΨm (R); progresses (G) ↔ preserved R, G Mitochondrial failure threshold Matches the “energy factory” targeting concept described in Oncomagnetic mechanism narratives
6 GSH depletion ↓ GSH (R→G) ↔ maintained R, G Loss of redox buffering Cancer-selective inability to restore GSH is a key discriminator vs normal cells
7 NRF2 response (selectivity gate) ↔ delayed/insufficient NRF2 (R→G) ↑ NRF2 (R→G) R, G Adaptive protection Normal-cell sparing is consistent with competent NRF2-driven antioxidant defense
8 ER stress / UPR (CHOP commitment) ↑ ER stress (R); CHOP/apoptotic UPR (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis failure ETC/ROS stress propagates to ER; commitment vs resolution diverges by cell robustness
9 DNA damage (oxidative; checkpoint markers) ↑ DNA damage (R→G) ↔ or repaired (G) R, G Checkpoint stress Interpreted as ROS-mediated consequence; reported as increased damage markers in some translational datasets
10 LDH / glycolytic vulnerability ↓ LDH performance / ↓ glycolytic flux (R→G) ↔ metabolic flexibility R, G Metabolic choke Cancer glycolysis becomes unstable when NADH/NAD+ and redox buffering are stressed
11 TrxR / thioredoxin system overload ↓ reserve (R→G) ↔ preserved R, G Parallel antioxidant collapse Useful when GSH data are mixed; TrxR can be the limiting system under sustained ROS 
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.
MyD88, Myeloid differentiation factor 88: Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
A gene that encodes a cytosolic adapter protein necessary for both innate and adaptive immune response.
The expression of MyD88 is elevated in tumor tissues compared to normal tissues, such as those found in breast, lung, liver, colon, and stomach organs.
Researchers have drawn contradictory conclusions regarding the role of MyD88 therein. The reason may be, on one hand, inhibiting MyD88 may weaken immune function, resulting in compromised immune surveillance against tumor cells and a reduced ability to eliminate pathogenic factors. This scenario can promote the emergence and progression of tumors. On the other hand, suppressing MyD88 might alleviate inflammation, thus preventing inflammation-associated tumorigenesis.
MYD88 (myeloid differentiation primary response 88) is a key adaptor protein involved in the signaling pathways of the immune system, particularly in the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) pathways.
Elevated MYD88 expression or the presence of MYD88 mutations can be associated with poor prognosis in certain cancers.


Scientific Papers found: Click to Expand⟱
204- MFrot,  MF,    Rotating magnetic field improved cognitive and memory impairments in a sporadic ad model of mice by regulating microglial polarization
- in-vivo, AD, NA
*NF-kB↓, *MAPK↓, *TLR4↓, *memory↑, *cognitive↑, *TGF-β1↑, *ARG↑, *IL4↑, *IL10↑, *IL6↓, *IL1↓, *TNF-α↓, *iNOS↓, *ROS↓, *NO↓, *MyD88↓, *p‑IKKα↓, *p‑IκB↓, *p‑p65↓, *p‑JNK↓, *p‑p38↓, *ERK↓, *neuroP↑, *Aβ↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Cell Death ⓘ

iNOS↓, 1,   p‑JNK↓, 1,   MAPK↓, 1,   p‑p38↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,  

Migration ⓘ

ARG↑, 1,   TGF-β1↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

p‑IKKα↓, 1,   IL1↓, 1,   IL10↑, 1,   IL4↑, 1,   IL6↓, 1,   p‑IκB↓, 1,   MyD88↓, 1,   NF-kB↓, 1,   p‑p65↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   memory↑, 1,   neuroP↑, 1,  
Total Targets: 25

Scientific Paper Hit Count for: MyD88, Myeloid differentiation factor 88
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:192  Target#:564  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page